Ignite Creation Date:
2024-05-05 @ 5:21 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00431561
Status:
COMPLETED
Last Update Posted:
2013-12-03
First Post:
2007-02-05
Brief Title:
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
Sponsor:
Isarna Therapeutics GmbH
Organization:
Isarna Therapeutics GmbH
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Anaplastic Astrocytoma |
| Glioblastoma |
Keywords:
| Name | View |
|---|---|
| Glioblastoma | View |
| Anaplastic astrocytoma | View |
| Antisense | View |
| Cancer | View |
| Transforming growth factor beta2 TGF-beta2 | View |
| Targeted therapy | View |
| Immunotherapy | View |
| Brain tumor | View |
| Central nervous system CNS | View |
| Convection-enhanced delivery CED microperfusion | View |
| Locoregional application | View |